Value of Insight
Consulting firm focused on the pharmaceutical and biopharmaceutical industries since 1998. Provides empirical research, quantitative analytics, and strategic advisory across drug development, regulatory strategy, commercialization, geospatial analysis for clinical trials, investment valuation, and litigation support.
Industries
Nr. of Employees
small (1-50)
Products
Geospatial Intelligence - Mapping Capabilities Presentation
Presentation of GIS-based analytical methods for clinical trial mapping, site selection, and patient recruitment optimization.
Case studies & whitepapers (selected)
Collection of whitepapers and case studies on market entry via generic acquisition, pharmaceutical market utilization trends, pricing for hospital equipment, and marketing ROI analyses.
Geospatial Intelligence - Mapping Capabilities Presentation
Presentation of GIS-based analytical methods for clinical trial mapping, site selection, and patient recruitment optimization.
Case studies & whitepapers (selected)
Collection of whitepapers and case studies on market entry via generic acquisition, pharmaceutical market utilization trends, pricing for hospital equipment, and marketing ROI analyses.
Services
Market assessment, pricing and reimbursement strategy, sales-force planning, ROI analysis, segmentation, and market-entry planning for branded and generic drugs.
Protocol and endpoint selection, regulatory submission preparation across multiple approval pathways, incorporation of international regulatory practices, and patient recruitment optimization.
GIS-based analyses to optimize clinical trial site selection, patient recruitment, and commercial territory planning using population and epidemiologic data.
Due diligence, probabilistic valuation models, portfolio analysis, and transaction support for investors and corporate development teams.
Expert witness testimony and analytical support on antitrust, patent and trademark disputes, lost profits modeling, regulatory compliance, and contract disputes.
Design and execution of primary research involving KOLs, payers, prescribers, patients, and other stakeholders across international markets.
Market assessment, pricing and reimbursement strategy, sales-force planning, ROI analysis, segmentation, and market-entry planning for branded and generic drugs.
Protocol and endpoint selection, regulatory submission preparation across multiple approval pathways, incorporation of international regulatory practices, and patient recruitment optimization.
GIS-based analyses to optimize clinical trial site selection, patient recruitment, and commercial territory planning using population and epidemiologic data.
Due diligence, probabilistic valuation models, portfolio analysis, and transaction support for investors and corporate development teams.
Expert witness testimony and analytical support on antitrust, patent and trademark disputes, lost profits modeling, regulatory compliance, and contract disputes.
Design and execution of primary research involving KOLs, payers, prescribers, patients, and other stakeholders across international markets.
Expertise Areas
- Clinical trial optimization and site selection
- Regulatory strategy and submissions
- Commercialization and market access
- Geospatial intelligence for clinical and commercial planning
Key Technologies
- Geographic Information Systems (GIS) and mapping
- Epidemiologic and geodemographic modeling
- Monte Carlo and stochastic simulation
- Econometric forecasting models
News & Updates
Presentation and whitepaper describing GIS-based methods for clinical trial mapping and patient recruitment.
Whitepaper discussing market entry strategies via acquisition of ANDA portfolios and impacts of low-cost manufacturing on generic markets.
Whitepaper analyzing shifts in U.S. pharmaceutical approvals and utilization patterns from the 1990s to 2000s.
Presentation and whitepaper describing GIS-based methods for clinical trial mapping and patient recruitment.
Whitepaper discussing market entry strategies via acquisition of ANDA portfolios and impacts of low-cost manufacturing on generic markets.
Whitepaper analyzing shifts in U.S. pharmaceutical approvals and utilization patterns from the 1990s to 2000s.